title: Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age.
abstract: We used nonpegylated liposomal doxorubicin (NPLD) in cytostatic drug combinations to treat 37 patients with non-Hodgkin's lymphoma and pre-existing cardiac disorder or elderly patients with reduced physical state who were ineligible for conventional anthracycline-containing therapy. High remission rates were observed in this poor-risk population: Complete remission rates were 75% for diffuse large B cell lymphoma (DLBCL) and 55% for T/NK cell neoplasm (overall response rate of 80% and 89%, respectively). Twenty-seven patients (73%) are still alive after a median observation time of 14 months. No major cardiac or gastrointestinal toxicity was observed. Extravasation of NPLD in two patients resulted in mild inflammation without tissue damage. Hematologic toxicity was comparable to that of conventional anthracycline-containing regimens. We conclude that NPLD is highly active in combination chemotherapy for lymphoma with low cardiac toxicity in patients with pre-existing cardiac disorders or higher age. Moreover, we also observed remarkable efficacy in T/NK cell lymphomas.
authors.affiliation: Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
authors.forename: Daniel
authors.initials: D
authors.lastname: Heintel
authors.forename: Cathrin
authors.initials: C
authors.lastname: Skrabs
authors.forename: Alexander
authors.initials: A
authors.lastname: Hauswirth
authors.forename: Karin
authors.initials: K
authors.lastname: Eigenberger
authors.forename: Christine
authors.initials: C
authors.lastname: Einberger
authors.forename: Markus
authors.initials: M
authors.lastname: Raderer
authors.forename: Wolfgang R
authors.initials: WR
authors.lastname: Sperr
authors.forename: Paul
authors.initials: P
authors.lastname: Knöbl
authors.forename: Leonhard
authors.initials: L
authors.lastname: Müllauer
authors.forename: Martin
authors.initials: M
authors.lastname: Uffmann
authors.forename: Karin
authors.initials: K
authors.lastname: Dieckmann
authors.forename: Alexander
authors.initials: A
authors.lastname: Gaiger
authors.forename: Ulrich
authors.initials: U
authors.lastname: Jäger
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006331:Heart Diseases / Q000150:complications*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin